HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

monafram

the F(ab')2 fragment of monoclonal antibody CRC64; approved for clinical use in the Russian Federation

Networked: 3 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Mazurov, A V: 2 articles (01/2010 - 05/2004)
2.	Pevzner, D V: 2 articles (01/2010 - 05/2004)
3.	Barsukov, A V: 1 article (01/2020)
4.	Kozlov, K L: 1 article (01/2020)
5.	Pavlovich, I M: 1 article (01/2020)
6.	Petrov, A S: 1 article (01/2020)
7.	Tuchkov, D Y: 1 article (01/2020)
8.	Yakovlev, V A: 1 article (01/2020)
9.	Yakovlev, V V: 1 article (01/2020)
10.	Frolova, N S: 1 article (01/2010)

Related Diseases

1.	Hemorrhage 01/01/2020 - "Bivalirudin was shown to be highly effective in comparison with unfractionated heparin and monafram in relation to the amount of bleeding that occurs in the postoperative period and adverse cardiovascular complications. "
2.	Acute Coronary Syndrome 01/01/2010 - "Efficacy and safety of monafram in primary coronary angioplasty of patients with acute coronary syndrome without ST segment elevation (non ST ACS) was evaluated in this study. " 01/01/2010 - "[Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation]."
3.	Myocardial Ischemia (Ischemic Heart Diseases) 05/01/2004 - "Monafram clinical trials were performed in healthy volunteers (n = 10) and in patients with ischemic heart disease undergoing high risk coronary angioplasty (n = 153). "
4.	Myocardial Infarction 01/01/2010 - "Within 30 days of follow up period monafram decreased by more than 2.5 fold the total amount of unfavorable outcomes (cardiovascular death, myocardial infarction and indications for repeat revascularization due to angina recurrence) - from 19.2% to 7.4% (p<0.001). " 05/01/2004 - "Within one month after coronary angioplasty Monafram decreased the number of end points (fatal and nonfatal myocardial infarction and angina recurrence) from 11.4 to 3.3%."
5.	Hypersensitivity (Allergy) 01/01/2010 - "Monafram did not cause any allergic reaction in all tested patients. " 05/01/2004 - "Major bleedings and allergic reactions were detected in none of patients, deep thrombocytopenia--in one patient and antibodies against Monafram--in 5% of patients. "

Related Drugs and Biologics

1.	Heparin (Liquaemin)
2.	bivalirudin (Angiomax)
3.	Glycoproteins (Glycoprotein)
4.	Antibodies